Today, 1,000 Shares of DexCom Inc. (DXCM) are sold by State of Wisconsin Investment Board

Today, 1,000 Shares of DexCom Inc. (DXCM) are sold by State of Wisconsin Investment Board
State of Wisconsin Investment Board lowered its stake in shares of DexCom Inc. (NASDAQ:DXCM) by 1.9% during the third quarter, Holdings Channel reports. The firm owned 52,630 shares of the medical device company’s stock after selling 1,000 shares during the period. State of Wisconsin Investment Board owned about 0.06% of DexCom worth $4,614,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. Public Employees Retirement Association of Colorado increased its stake in DexCom by 0.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 19,466 shares of the medical device company’s stock valued at $1,544,000 after buying an additional 94 shares during the period. Hsbc Holdings PLC increased its stake in DexCom by 2.6% in the second quarter. Hsbc Holdings PLC now owns 3,944 shares of the medical device company’s stock valued at $313,000 after buying an additional 100 shares during the period. Eqis Capital Management Inc. increased its stake in DexCom by 1.7% in the second quarter. Eqis Capital Management Inc. now owns 7,246 shares of the medical device company’s stock valued at $575,000 after buying an additional 119 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in DexCom by 4.0% in the second quarter. Metropolitan Life Insurance Co. NY now owns 6,183 shares of the medical device company’s stock valued at $490,000 after buying an additional 239 shares during the period. Finally, Legal & General Group Plc increased its stake in DexCom by 4.7% in the second quarter. Legal & General Group Plc now owns 5,412 shares of the medical device company’s stock valued at $430,000 after buying an additional 241 shares during the period.

Shares of DexCom Inc. (NASDAQ:DXCM) traded up 0.87% during midday trading on Friday, reaching $72.82. 472,540 shares of the company were exchanged. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The company has a 50 day moving average price of $74.17 and a 200-day moving average price of $79.91. The stock’s market capitalization is $6.16 billion.

Several equities research analysts have commented on the stock. B. Riley assumed coverage on shares of DexCom in a report on Sunday, October 2nd. They set a “neutral” rating and a $97.00 price objective on the stock. Jefferies Group reaffirmed a “buy” rating and set a $98.00 price objective on shares of DexCom in a report on Wednesday, August 3rd. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $100.00 price objective on shares of DexCom in a report on Wednesday, August 3rd. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $100.00 price objective (up from $93.00) on shares of DexCom in a report on Thursday, August 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $92.00 price objective on shares of DexCom in a report on Thursday, August 4th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $92.07.

In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $92.14, for a total transaction of $921,400.00. Following the completion of the sale, the insider now directly owns 451,486 shares in the company, valued at approximately $41,599,920.04. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Terrance H. Gregg sold 10,740 shares of the business’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $95.29, for a total value of $1,023,414.60. Following the sale, the insider now owns 451,486 shares of the company’s stock, valued at $43,022,100.94. The disclosure for this sale can be found here. Company insiders own 2.80% of the company’s stock.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Related posts

Leave a Comment